



## LIFECARE ASA: MANDATORY NOTIFICATION OF TRADE

**Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") on 22 January 2026 regarding the final results of the rights issue of new shares in the Company, with the allocation of 160,000,000 new shares (the "Offer Shares") at the subscription price of NOK 0.50 per share, raising gross proceeds of NOK 80 million (the "Rights Issue").**

Subscribers in the Rights Issue will, without cost, receive warrants in two series: (a) three (3) warrants for every four (4) Offer Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 2 March 2026 to 13 March 2026 ("**Warrants Series 1**"); and (b) three (3) warrants for every four (4) Offer Shares allocated to, and paid by, them in the Rights Issue, which will be exercisable in the exercise period from 1 June 2026 to 12 June 2026 ("**Warrants Series 2**" and together with Warrants Series 1, the "**Warrants**").

Reference is further made to the stock exchange announcement made by the Company on 14 January 2026, regarding the subscription of Offer Shares and Warrants in the Rights Issue by Hannibal Invest AS, a company closely associated with Hans Hekland, board member of the Company. Following the allocation of Offer Shares by the Company, Hans Hekland has been allocated in total 820,261 Offer Shares, of which 200,000 Offer Shares were allocated based on exercise of subscription rights and over-subscription (as notified on 14 January 2026), and 620,261 Offer Shares were allocated pursuant to Hekland's underwriting obligation for the Rights Issue. Further, based on the number of Offer Shares allocated, Hekland has been allocated in total 1,230,392 Warrants. The allocations have been made to Hekland personally and not to Hannibal Invest AS as initially indicated.

Please see the attached PDMR form for further details.

### About us

Lifecare ASA is a medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring systems to market. Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor technology is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

## **Contacts**

For further information, please contact:

Joacim Holter, CEO, [joacim.holter@lifecare.no](mailto:joacim.holter@lifecare.no), +47 40 05 90 40

Renete Kaarvik, CFO, [renete.kaarvik@lifecare.no](mailto:renete.kaarvik@lifecare.no), +47 94 83 82 42

*This information is subject to disclosure under the Norwegian Securities Trading Act, §5-12. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-01-23 14:55 CET.*

## **Attachments**

[PDMR Attachment](#)